Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results

Dr. John Fleetham chats with Dr. Kelly Dooley about her paper, "Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results."

Show Notes

Paper discussed in today's episode:
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results

What is Out of the Blue: An AJRCCM Podcast?

The Out of the Blue podcast takes you out of the pages of the American Journal of Respiratory and Critical Care Medicine and into the minds of the most brilliant researchers in the fields of respiratory, critical care, and sleep medicine.